Safety considerations with fenofibrate/simvastatin combination.

Safety considerations with fenofibrate/simvastatin combination.

Item
http://www.wikidata.org/entity/Q38541832
Pitavastatin and carbohydrate metabolism: what is the evidence?Fenofibrate/simvastatin fixed-dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy.Acid-base and electrolyte disorders associated with the use of antidiabetic drugs.PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part I: PPAR-α.The safety of ezetimibe and simvastatin combination for the treatment of hypercholesterolemia.Cholesteryl ester transfer protein inhibitors: challenges and perspectives.Pharmacological management of diabetic dyslipidemia.Review. The role of peroxisome proliferator-activated receptor in the treatment of non-alcoholic fatty liver disease.PPAR-α agonists are still on the rise: an update on clinical and experimental findings.Chronic kidney disease stage affects small, dense low-density lipoprotein but not glycated low-density lipoprotein in younger chronic kidney disease patients: a cross-sectional study.
P2860

Safety considerations with fenofibrate/simvastatin combination.

Item
http://www.wikidata.org/entity/Q38541832
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Safety considerations with fenofibrate/simvastatin combination.
@en
type
label
Safety considerations with fenofibrate/simvastatin combination.
@en
prefLabel
Safety considerations with fenofibrate/simvastatin combination.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P698
P356
P1433
P1476
Safety considerations with fenofibrate/simvastatin combination
@en
P2093
P2860
P304
P31
P356
10.1517/14740338.2015.1056778
P407
P433
P478
P50
P577
P698